Literature DB >> 12370371

Uniquely conformed peptide-containing beta 2-microglobulin-free heavy chains of HLA-B2705 on the cell surface.

Pratap Malik1, Polina Klimovitsky, Lih-Wen Deng, Jonathan E Boyson, Jack L Strominger.   

Abstract

The human class I MHC molecules are known to generally exist on the cell surface either as peptide-containing complexes of H chain (alpha-chain) and beta(2)-microglobulin (beta(2)m) or as beta(2)m-free H chains incapable of binding peptides. In this study, a uniquely conformed peptide-containing beta(2)m-free HLA-B2705 H chain has been isolated using the recently described highly efficient perfusion-affinity chromatography system for purification of class I MHC protein molecules. This form recognized by the mAb MARB4 is very closely associated with the remainder of the peptide containing HLA-B2705/beta(2)m complex reactive with mAb ME1 and is present to approximately 1-10% of mAb ME1 reactive forms on the cell surface. Also, HLA-B2705 purified using the mAb ME1 affinity column includes this unique mAb MARB4-reactive, unusually stable peptide-containing beta(2)m-free form. A peptide nonamer GRWRGWYTY was isolated and identified from this beta(2)m-free HLA-B2705 H chain and was used to assemble the mAb MARB4 reactive form efficiently on the surface of cells expressing HLA-B2705. The discovery of this form opens new avenues for further investigation of the role of HLA-B27 in spondyloarthropathies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12370371     DOI: 10.4049/jimmunol.169.8.4379

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

Review 1.  HLA-B27-associated reactive arthritis: pathogenetic and clinical considerations.

Authors:  Inés Colmegna; Raquel Cuchacovich; Luis R Espinoza
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

Review 2.  Towards a systems understanding of MHC class I and MHC class II antigen presentation.

Authors:  Jacques Neefjes; Marlieke L M Jongsma; Petra Paul; Oddmund Bakke
Journal:  Nat Rev Immunol       Date:  2011-11-11       Impact factor: 53.106

3.  Therapeutic monoclonal antibodies for multiple myeloma: an update and future perspectives.

Authors:  Jing Yang; Qing Yi
Journal:  Am J Blood Res       Date:  2011-06-15

4.  Shigella induced reactive arthritis.

Authors:  J S Hill Gaston
Journal:  Ann Rheum Dis       Date:  2005-04       Impact factor: 19.103

5.  The Human Leukocyte Antigen (HLA)-B27 Peptidome in Vivo, in Spondyloarthritis-susceptible HLA-B27 Transgenic Rats and the Effect of Erap1 Deletion.

Authors:  Eilon Barnea; Dganit Melamed Kadosh; Yael Haimovich; Nimman Satumtira; Martha L Dorris; Mylinh T Nguyen; Robert E Hammer; Tri M Tran; Robert A Colbert; Joel D Taurog; Arie Admon
Journal:  Mol Cell Proteomics       Date:  2017-02-10       Impact factor: 5.911

6.  ERAP1 reduces accumulation of aberrant and disulfide-linked forms of HLA-B27 on the cell surface.

Authors:  Tri M Tran; Sohee Hong; Jehad H Edwan; Robert A Colbert
Journal:  Mol Immunol       Date:  2016-04-22       Impact factor: 4.407

7.  Disulfide bond-mediated dimerization of HLA-G on the cell surface.

Authors:  Jonathan E Boyson; Robert Erskine; Mary C Whitman; Michael Chiu; Julie M Lau; Louise A Koopman; Markus M Valter; Pavla Angelisova; Vaclav Horejsi; Jack L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-26       Impact factor: 11.205

Review 8.  From HLA-B27 to spondyloarthritis: a journey through the ER.

Authors:  Robert A Colbert; Monica L DeLay; Erin I Klenk; Gerlinde Layh-Schmitt
Journal:  Immunol Rev       Date:  2010-01       Impact factor: 12.988

Review 9.  HLA-B27 misfolding and spondyloarthropathies.

Authors:  Robert A Colbert; Monica L DeLay; Gerlinde Layh-Schmitt; Dawn P Sowders
Journal:  Prion       Date:  2009-01-03       Impact factor: 3.931

10.  Adopting the rapamycin trapping assay to track the trafficking of murine MHC class I alleles, H-2K(b).

Authors:  Esther Ghanem; Mohammed Al-Balushi
Journal:  BMC Cell Biol       Date:  2015-12-29       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.